Collegium Pharmaceutical, Inc. Logo

Collegium Pharmaceutical, Inc.

COLL

(0.8)
Stock Price

29,97 USD

17.62% ROA

49.14% ROE

12.34x PER

Market Cap.

1.224.768.676,00 USD

255.73% DER

0% Yield

17.32% NPM

Collegium Pharmaceutical, Inc. Stock Analysis

Collegium Pharmaceutical, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Collegium Pharmaceutical, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 Buffet Intrinsic Value

The company's stock seems undervalued (1.294) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

3 ROE

Negative ROE (-5.78%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-1.9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (4.33x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The company has a high debt to equity ratio (380%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Collegium Pharmaceutical, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Collegium Pharmaceutical, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Collegium Pharmaceutical, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Collegium Pharmaceutical, Inc. Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 1.711.000 100%
2017 28.476.000 93.99%
2018 280.413.000 89.84%
2019 296.701.000 5.49%
2020 310.016.000 4.29%
2021 276.868.000 -11.97%
2022 463.933.000 40.32%
2023 546.836.000 15.16%
2023 566.767.000 3.52%
2024 581.104.000 2.47%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Collegium Pharmaceutical, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 14.157.000
2014 14.959.000 5.36%
2015 7.975.000 -87.57%
2016 14.948.000 46.65%
2017 8.572.000 -74.38%
2018 8.661.000 1.03%
2019 10.340.000 16.24%
2020 9.772.000 -5.81%
2021 9.451.000 -3.4%
2022 3.983.000 -137.28%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Collegium Pharmaceutical, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 1.885.000
2014 2.706.000 30.34%
2015 18.932.000 85.71%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 108.464.000 100%
2021 114.774.000 5.5%
2022 160.443.000 28.46%
2023 0 0%
2023 151.802.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Collegium Pharmaceutical, Inc. EBITDA
Year EBITDA Growth
2013 -15.873.000
2014 -17.478.000 9.18%
2015 -26.907.000 35.04%
2016 -94.082.000 71.4%
2017 -74.853.000 -25.69%
2018 -18.998.000 -294%
2019 -21.813.000 12.91%
2020 56.464.000 138.63%
2021 22.218.000 -154.14%
2022 34.366.000 35.35%
2023 346.812.000 90.09%
2023 331.832.000 -4.51%
2024 331.752.000 -0.02%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Collegium Pharmaceutical, Inc. Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 -171.000 100%
2016 1.498.000 111.42%
2017 25.881.000 94.21%
2018 114.736.000 77.44%
2019 103.041.000 -11.35%
2020 179.836.000 42.7%
2021 150.617.000 -19.4%
2022 209.488.000 28.1%
2023 321.244.000 34.79%
2023 326.169.000 1.51%
2024 363.224.000 10.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Collegium Pharmaceutical, Inc. Net Profit
Year Net Profit Growth
2013 -16.197.000
2014 -17.917.000 9.6%
2015 -27.255.000 34.26%
2016 -94.176.000 71.06%
2017 -74.865.000 -25.79%
2018 -39.128.000 -91.33%
2019 -8.148.000 -380.22%
2020 26.752.000 130.46%
2021 71.517.000 62.59%
2022 -25.002.000 386.05%
2023 82.536.000 130.29%
2023 48.155.000 -71.4%
2024 78.424.000 38.6%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Collegium Pharmaceutical, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -2
2014 -2 0%
2015 -2 0%
2016 -4 33.33%
2017 -2 -50%
2018 -1 -100%
2019 0 0%
2020 1 0%
2021 2 100%
2022 -1 0%
2023 2 100%
2023 1 -100%
2024 2 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Collegium Pharmaceutical, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -16.736.000
2014 -17.955.000 6.79%
2015 -21.929.000 18.12%
2016 -78.030.000 71.9%
2017 -68.008.000 -14.74%
2018 145.036.000 146.89%
2019 21.345.000 -579.48%
2020 -279.830.000 107.63%
2021 101.613.000 375.39%
2022 122.608.000 17.12%
2023 274.288.000 55.3%
2023 73.953.000 -270.9%
2024 67.128.000 -10.17%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Collegium Pharmaceutical, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -16.530.000
2014 -17.947.000 7.9%
2015 -21.567.000 16.78%
2016 -75.053.000 71.26%
2017 -67.018.000 -11.99%
2018 169.390.000 139.56%
2019 27.783.000 -509.69%
2020 93.942.000 70.43%
2021 103.557.000 9.28%
2022 124.230.000 16.64%
2023 274.749.000 54.78%
2023 74.018.000 -271.19%
2024 67.398.000 -9.82%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Collegium Pharmaceutical, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 206.000
2014 8.000 -2475%
2015 362.000 97.79%
2016 2.977.000 87.84%
2017 990.000 -200.71%
2018 24.354.000 95.93%
2019 6.438.000 -278.29%
2020 373.772.000 98.28%
2021 1.944.000 -19126.95%
2022 1.622.000 -19.85%
2023 461.000 -251.84%
2023 65.000 -609.23%
2024 270.000 75.93%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Collegium Pharmaceutical, Inc. Equity
Year Equity Growth
2013 5.582.000
2014 -12.241.000 145.6%
2015 85.072.000 114.39%
2016 134.908.000 36.94%
2017 104.080.000 -29.62%
2018 91.585.000 -13.64%
2019 87.432.000 -4.75%
2020 186.031.000 53%
2021 202.928.000 8.33%
2022 194.842.000 -4.15%
2023 195.431.000 0.3%
2023 178.873.000 -9.26%
2024 216.583.000 17.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Collegium Pharmaceutical, Inc. Assets
Year Assets Growth
2013 9.034.000
2014 5.090.000 -77.49%
2015 97.718.000 94.79%
2016 162.017.000 39.69%
2017 135.568.000 -19.51%
2018 291.245.000 53.45%
2019 306.302.000 4.92%
2020 643.841.000 52.43%
2021 692.077.000 6.97%
2022 1.174.131.000 41.06%
2023 1.143.308.000 -2.7%
2023 1.177.578.000 2.91%
2024 1.053.387.999 -11.79%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Collegium Pharmaceutical, Inc. Liabilities
Year Liabilities Growth
2013 3.452.000
2014 17.331.000 80.08%
2015 12.646.000 -37.05%
2016 27.109.000 53.35%
2017 31.488.000 13.91%
2018 199.660.000 84.23%
2019 218.870.000 8.78%
2020 457.810.000 52.19%
2021 489.149.000 6.41%
2022 979.289.000 50.05%
2023 947.877.000 -3.31%
2023 998.705.000 5.09%
2024 836.805.000 -19.35%

Collegium Pharmaceutical, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
17.78
Net Income per Share
3.08
Price to Earning Ratio
12.34x
Price To Sales Ratio
2.12x
POCF Ratio
4.46
PFCF Ratio
4.44
Price to Book Ratio
5.69
EV to Sales
2.79
EV Over EBITDA
4.53
EV to Operating CashFlow
5.82
EV to FreeCashFlow
5.85
Earnings Yield
0.08
FreeCashFlow Yield
0.23
Market Cap
1,22 Bil.
Enterprise Value
1,61 Bil.
Graham Number
21.51
Graham NetNet
-12.74

Income Statement Metrics

Net Income per Share
3.08
Income Quality
2.77
ROE
0.49
Return On Assets
0.09
Return On Capital Employed
0.34
Net Income per EBT
0.71
EBT Per Ebit
0.69
Ebit per Revenue
0.35
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.62
Operating Profit Margin
0.35
Pretax Profit Margin
0.24
Net Profit Margin
0.17

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
8.53
Free CashFlow per Share
8.5
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0.01
Return on Invested Capital
0.19
Return on Tangible Assets
0.18
Days Sales Outstanding
116.37
Days Payables Outstanding
4.01
Days of Inventory on Hand
46.34
Receivables Turnover
3.14
Payables Turnover
90.98
Inventory Turnover
7.88
Capex per Share
0.03

Balance Sheet

Cash per Share
8,38
Book Value per Share
6,68
Tangible Book Value per Share
-8.32
Shareholders Equity per Share
6.68
Interest Debt per Share
19.33
Debt to Equity
2.56
Debt to Assets
0.53
Net Debt to EBITDA
1.09
Current Ratio
1.11
Tangible Asset Value
-0,27 Bil.
Net Current Asset Value
-0,33 Bil.
Invested Capital
555582000
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.46
Average Receivables
0,18 Bil.
Average Payables
0,00 Bil.
Average Inventory
29569000
Debt to Market Cap
0.45

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Collegium Pharmaceutical, Inc. Dividends
Year Dividends Growth

Collegium Pharmaceutical, Inc. Profile

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CEO
Mr. Michael Thomas Heffernan B
Employee
197
Address
100 Technology Center Drive
Stoughton, 02072

Collegium Pharmaceutical, Inc. Executives & BODs

Collegium Pharmaceutical, Inc. Executives & BODs
# Name Age
1 Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Co-Founder, Chairman, Interim Chief Executive Officer & President
70
2 Ms. Colleen Tupper
Executive Vice President & Chief Financial Officer
70
3 Ms. Shirley R. Kuhlmann
Executive Vice President, General Counsel, Chief Administrative Officer & Secretary
70
4 Dr. Thomas B. Smith FAAFP, M.D.
Executive Vice President & Chief Medical Officer
70
5 Mr. Scott Sudduth
Head of Technical Operations
70
6 Dr. Christopher Shayne James M.D.
Vice President of Investor Relations
70
7 Mr. Scott Dreyer
Executive Vice President & Chief Commercial Officer
70
8 Mr. Bart J. Dunn
Executive Vice President of Strategy & Corporate Development
70

Collegium Pharmaceutical, Inc. Competitors